Navigation Links
DS Chemphy Focusing on CRO/CMO Business
Date:2/9/2010

WILMINGTON, Del., Feb. 9 /PRNewswire/ -- The rapid increase of cost in China has brought some shadow to the CRO and CMO businesses there. However, DS Chemphy, Inc., a USA-based contract research and manufacturing organization that focuses on fine and pharmaceutical chemicals, continues investing in its businesses. "Our competitive advantages are not only low costs," said Dr. Aaron Shen, CEO of the company.

Dr. Shen continues: "What makes Chemphy so attractive to our customers? The answers are: high-standard EHS management, high quality products and services, proprietary technologies, high efficiency, excellent IP protection, active communication, and integrated capability from R&D to manufacture."

Since DS Chemphy acquired New Chemphy in 2007, DS Chemphy has invested over $45 million in CRO/CMO capability as well as corporate culture and management reform. New Chemphy was founded by the Chinese Academy of Sciences. DS Chemphy integrated Chinese and Western advantages, i.e. lower costs of China and high-standard quality management of the West. The successful story was reported by C&E News (Issue Sept 1, 2008, page 35).

Most senior executives of the company have overseas training or work experience. The company now employs over 1000 chemical professionals. Last year, the company built a world-class R&D center. 150 chemists, including 25 PhDs, work in the center. The labs are equipped with state-of-the-art instruments including NMR, LC-MS, GC-MS, DSC, RC1, and GPC. The company has two manufacturing sites capable of production at pilot, multi-functional, and commercial scale. The reactors cover all sizes up to 20M(3). The reactors are either made of stainless steel, or glass-lined, nickel-lined, titanium-lined, Hastelloy-lined or polytetrafluoroethylene-lined.

DS Chemphy offers quality products based on Chemphy proprietary technology platforms including cyclopropanation, fluorination, and catalytic continues process, etc.

Recently DS Chemphy launched three new products:

Cyclopentyl methyl ether -- THF alternative

ChemphySteel® -- Polymers as strong as steel

ChemphyFresh® -- Keep your fruits and vegetables fresh

Visit us at booth 117 at InformEx USA, San Francisco, CA February 16-19, 2010, or www.dschemphy.com. You may also contact Aaron Shen, President of DS Chemphy at tel: 302-351-8401, fax: 302-351-6101 or email: ashen@dschemphy.com.

SOURCE DS Chemphy, Inc.

RELATED LINKS
http://www.dschemphy.com

'/>"/>

SOURCE DS Chemphy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
2. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
3. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
4. Babson Executive Education Offers Bio-Pharma: Mastering the Business of Science
5. Centerphase Solutions, Inc. Launches New Clinical Trials Business Model Company
6. Kantar Health and ImpactRx Launch CancerMPact Monthly Drugs and Regimens for Oncology Business Decisions
7. Los Angeles Business Owner Pleads Guilty to Submitting Nearly $1 Million in False and Fraudulent Claims to Medicare
8. Highlights of Economic and Business Growth in the Tampa Bay Region
9. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
10. PDI Announces New Pharmaceutical Services Business Win With a Top 5 Pharmaceutical Company
11. Pfizer Whistleblower Named Years Most Influential Person In Business Ethics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first approach, layered with ... every IT system, from the datacenter to the cloud to the edge. Through ...
(Date:5/24/2017)... ... 24, 2017 , ... The CFOs included on this list ... in the nation and help their organizations navigate the challenges in healthcare today. ... in developing successful hospital and health system strategy. , Becker's Hospital Review has ...
(Date:5/23/2017)... ... May 23, 2017 , ... MDLand International (MDLand), a ... today that its iClinic V12.2 solution has achieved approval from National Center for ... PCMH 2017 standards which emphasize team-based care with a significant focus on the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... 2017 , ... London, May 23, 2017: Walter Schindler, the Founder and Managing ... Guest Speaker and Contributor to a weeklong series of classes, meetings, field trips and ... , Walter Schindler and SAIL Capital have received an increasing number ...
Breaking Medicine News(10 mins):